<DOC>
	<DOCNO>NCT00075933</DOCNO>
	<brief_summary>ARQ 501 , investigational anticancer drug , intend selectively kill cancer cell spare normal cell restore activate cellular checkpoint know defective cancer use Company 's unique biology platform , Activated Checkpoint Therapyâ„¢ ( ACT ) . ARQ 501 potential improve activity reduce toxicity molecular approach traditional cancer chemotherapy .</brief_summary>
	<brief_title>ARQ 501 Subjects With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Beta-lapachone</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm solid tumor metastatic , unresectable recurrent standard curative palliative measure exist longer effective . ECOG performance status great equal 1 Life expectancy great three month Acceptable pretreatment clinical laboratory result Exclusion Criteria Subjects chemotherapy radiotherapy within 4 week Subjects receive investigational agent Subjects know untreated brain metastasis Subjects receive hepatic enzymeinducing antiseizure drug ( `` EIASD '' ) Subjects uncontrolled intercurrent illness Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>